KR100904788B1 - Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드 - Google Patents

Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드 Download PDF

Info

Publication number
KR100904788B1
KR100904788B1 KR1020037000784A KR20037000784A KR100904788B1 KR 100904788 B1 KR100904788 B1 KR 100904788B1 KR 1020037000784 A KR1020037000784 A KR 1020037000784A KR 20037000784 A KR20037000784 A KR 20037000784A KR 100904788 B1 KR100904788 B1 KR 100904788B1
Authority
KR
South Korea
Prior art keywords
compound
alkyl
conhch
mmol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037000784A
Other languages
English (en)
Korean (ko)
Other versions
KR20030025277A (ko
Inventor
아닐 케이. 삭세나
비요르 무필 기리자발라반
레이몬드 지. 러비
에드윈 이. 자오
프랭크 베넷
진핑 엘. 맥코믹
하이얀 왕
러셀 이. 파이크
스테판 엘. 보겐
틴-야우 찬
위-청 류
쟈오닝 쥬
에프. 죠지 은조로게
아쇼크 아라사판
테잘 엔. 파레크
아쉬트 케이. 갱굴리
케빈 엑스. 첸
스리칸쓰 벤카트라만
헨리 에이. 바카로
패트릭 에이. 핀토
바마 산타남
완리 우
시스카 핸드라타
유후아 후앙
스콧 제프리 켐프
오딜 에스터 레비
마르구에리타 림-윌비
수잔 와이. 타무라
Original Assignee
쉐링 코포레이션
덴드레온 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22822095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100904788(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 쉐링 코포레이션, 덴드레온 코포레이션 filed Critical 쉐링 코포레이션
Publication of KR20030025277A publication Critical patent/KR20030025277A/ko
Application granted granted Critical
Publication of KR100904788B1 publication Critical patent/KR100904788B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020037000784A 2000-07-21 2001-07-19 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드 Expired - Fee Related KR100904788B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22010800P 2000-07-21 2000-07-21
US60/220,108 2000-07-21
PCT/US2001/022678 WO2002008244A2 (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020097002011A Division KR100939155B1 (ko) 2000-07-21 2001-07-19 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제 억제제로서의신규한 펩티드

Publications (2)

Publication Number Publication Date
KR20030025277A KR20030025277A (ko) 2003-03-28
KR100904788B1 true KR100904788B1 (ko) 2009-06-25

Family

ID=22822095

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020037000784A Expired - Fee Related KR100904788B1 (ko) 2000-07-21 2001-07-19 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
KR1020097002011A Expired - Fee Related KR100939155B1 (ko) 2000-07-21 2001-07-19 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제 억제제로서의신규한 펩티드

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097002011A Expired - Fee Related KR100939155B1 (ko) 2000-07-21 2001-07-19 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제 억제제로서의신규한 펩티드

Country Status (31)

Country Link
US (4) US7012066B2 (enExample)
EP (1) EP1385870B1 (enExample)
JP (3) JP4298289B2 (enExample)
KR (2) KR100904788B1 (enExample)
CN (3) CN102206247B (enExample)
AR (2) AR033985A1 (enExample)
AT (1) ATE461207T1 (enExample)
AU (2) AU7698801A (enExample)
BR (1) BR0112540A (enExample)
CA (1) CA2410662C (enExample)
CY (2) CY1112267T1 (enExample)
CZ (1) CZ303213B6 (enExample)
DE (2) DE60141608D1 (enExample)
DK (1) DK1385870T3 (enExample)
EC (1) ECSP034438A (enExample)
ES (1) ES2341534T3 (enExample)
HU (1) HU229997B1 (enExample)
IL (2) IL153670A0 (enExample)
LU (1) LU91910I2 (enExample)
MX (1) MXPA03000627A (enExample)
MY (2) MY139078A (enExample)
NO (2) NO332329B1 (enExample)
NZ (1) NZ523782A (enExample)
PL (1) PL206255B1 (enExample)
PT (1) PT1385870E (enExample)
RU (2) RU2355700C9 (enExample)
SI (1) SI1385870T1 (enExample)
SK (1) SK288064B6 (enExample)
TW (1) TWI324611B (enExample)
WO (1) WO2002008244A2 (enExample)
ZA (1) ZA200210312B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101020355B1 (ko) * 2002-01-18 2011-03-08 덴드레온 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드

Families Citing this family (272)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN183120B (enExample) 1996-10-18 1999-09-11 Vertex Pharma
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
MY139078A (en) * 2000-07-21 2009-08-28 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6638926B2 (en) 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
EP1343807B1 (en) * 2000-12-12 2009-04-29 Schering Corporation Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
CA2432799C (en) 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1404704B9 (en) 2001-07-11 2008-02-20 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
WO2003035060A1 (en) * 2001-10-24 2003-05-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
TWI265927B (en) * 2002-01-23 2006-11-11 Schering Corp Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7273885B2 (en) * 2002-04-11 2007-09-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050090450A1 (en) * 2003-04-11 2005-04-28 Farmer Luc J. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
AU2004240704B9 (en) 2003-05-21 2009-10-22 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
CN1805931B (zh) * 2003-06-17 2010-06-23 先灵公司 制备(1r,2s,5s)-6,6-二甲基-3-氮杂双环[3,1,0]己烷-2-羧酸酯或其盐的方法和中间体
EP1633698A1 (en) * 2003-06-17 2006-03-15 Schering Corporation Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof
CN1852920B (zh) * 2003-07-18 2010-12-15 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
CA2536570A1 (en) * 2003-08-26 2005-03-10 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
AU2004274468B2 (en) * 2003-09-18 2009-07-23 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7642235B2 (en) 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7592419B2 (en) 2003-09-26 2009-09-22 Schering Corporation Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
EP1692157B1 (en) 2003-10-10 2013-04-17 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
CA2551074A1 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Hcv ns3-ns4a protease resistance mutants
JP2007532479A (ja) 2003-11-20 2007-11-15 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター
EP1742913A1 (en) * 2003-12-11 2007-01-17 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
CA2549851C (en) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
UA84050C2 (en) * 2004-01-30 2008-09-10 Медивир Аб Hcv ns-3-serine protease inhibitors
EP1711515A2 (en) * 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
WO2005085197A1 (en) * 2004-02-27 2005-09-15 Schering Corporation Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1737821B1 (en) * 2004-02-27 2009-08-05 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
RU2006134002A (ru) * 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
TW200602037A (en) * 2004-02-27 2006-01-16 Schering Corp Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
JP4745327B2 (ja) 2004-02-27 2011-08-10 シェーリング コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
ATE514691T1 (de) * 2004-02-27 2011-07-15 Schering Corp Neue ketoamide mit cyclischen p4 als inhibitoren der ns3-serinprotease von hepatitis-c-virus
ATE470660T1 (de) * 2004-02-27 2010-06-15 Schering Corp Schwefelverbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
KR101135765B1 (ko) * 2004-03-12 2012-04-23 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
AR049635A1 (es) * 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
WO2005113581A1 (en) * 2004-05-20 2005-12-01 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
MX2007002371A (es) 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
PL1802650T3 (pl) * 2004-10-01 2012-04-30 Scynexis Inc 3-Etero i 3-tioetero podstawione pochodne cyklosporyny do leczenia i zapobiegania zakażeniu wirusem zapalenia wątroby typu C
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
TW200621233A (en) 2004-10-01 2006-07-01 Vertex Pharma HCV NS3-NS4A protease inhibition
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
GB0426661D0 (en) * 2004-12-06 2005-01-05 Isis Innovation Pyrrolidine compounds
EP1919478B1 (en) * 2005-06-02 2016-03-23 Merck Sharp & Dohme Corp. Combination of hcv protease inhibitors with a surfactant
US20070021351A1 (en) * 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
WO2006130627A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis c
WO2006130626A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period
US20060276407A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
NZ563361A (en) * 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
AU2006252623A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis C virus
US20060276406A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
ZA200711069B (en) * 2005-06-30 2009-03-25 Virobay Inc HCV inhibitors
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
BRPI0613962A2 (pt) * 2005-07-25 2009-03-24 Intermune Inc inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
WO2007014924A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
MY139923A (en) 2005-07-29 2009-11-30 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
WO2007016589A2 (en) * 2005-08-02 2007-02-08 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
BRPI0615029A2 (pt) 2005-08-19 2009-06-16 Vertex Pharma processos e intermediários
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
JP5322647B2 (ja) * 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
US7754685B2 (en) * 2005-09-30 2010-07-13 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
DK1999129T3 (da) * 2005-10-11 2011-02-07 Intermune Inc Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus
WO2007056163A2 (en) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
JP5409008B2 (ja) 2005-11-11 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス改変体
AR056805A1 (es) * 2005-11-14 2007-10-24 Schering Corp Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
CA2634397A1 (en) * 2005-12-22 2007-07-05 Schering Corporation Process for the preparation of 6,6-dimethyl-3-azabicyclo[3.1.0|-hexane compounds and enantiomeric salts thereof
CA2634743C (en) 2005-12-23 2014-07-29 Zealand Pharma A/S Modified lysine-mimetic compounds
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1981523A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Novel hcv inhibitor combinations and methods
AR059429A1 (es) * 2006-02-09 2008-04-09 Schering Corp Combinaciones que involucran el (los) inhibidor(es) de la protesa hcv y metodos de tratamiento relacionados al (los) mismo (s)
EP2340836A1 (en) 2006-02-27 2011-07-06 Vertex Pharmceuticals Incorporated Co-crystals comprising VX-950 and their pharmaceutical compositions
WO2007106317A2 (en) * 2006-03-03 2007-09-20 Schering Corporation Pharmaceutical combinations of hcv-protease and -ires inhibitors
EP2007381A4 (en) * 2006-03-06 2010-11-17 Abbott Lab COMPOSITIONS AND METHODS OF USING RITONAVIR FOR THE TREATMENT OF HEPATITIS C VIRUS
NZ571280A (en) 2006-03-16 2011-10-28 Vertex Pharma Deuterated hepatitis C protease inhibitors
US7825152B2 (en) * 2006-04-11 2010-11-02 Novartis Ag Organic compounds and their uses
JP2009536158A (ja) * 2006-04-11 2009-10-08 ノバルティス アクチエンゲゼルシャフト Ｈｃｖ阻害剤
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
EP2012753A2 (en) * 2006-04-28 2009-01-14 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8188052B2 (en) 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
US7951823B2 (en) 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2007140117A1 (en) * 2006-05-23 2007-12-06 Irm Llc Compounds and compositions as channel activating protease inhibitors
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
MX2009000882A (es) 2006-08-17 2009-02-04 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
AU2007286754A1 (en) * 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
EP2066688A2 (en) * 2006-09-13 2009-06-10 Novartis AG Macrocyclic hcv inhibitors and their uses
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
EP2099778A2 (en) * 2006-11-21 2009-09-16 Smithkline Beecham Corporation Amido anti-viral compounds
JP2010510245A (ja) * 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス化合物
US20100081672A1 (en) * 2006-12-07 2010-04-01 Schering Corporation Ph sensitive matrix formulation
MX2009006477A (es) * 2006-12-15 2009-06-26 Schering Corp Purificacion de bisulfito de una alfa-ceto amida.
US8163937B2 (en) * 2006-12-20 2012-04-24 Schering Corporation Process for preparing (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
ES2558856T3 (es) 2006-12-21 2016-02-09 Zealand Pharma A/S Síntesis de compuestos de pirrolidina
US8268803B2 (en) 2006-12-22 2012-09-18 Merck Sharp & Dohme Corp. 5, 6-ring annulated indole derivatives and use thereof
MX2009006878A (es) * 2006-12-22 2009-07-07 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
KR20090094154A (ko) 2006-12-22 2009-09-03 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
CN101600428A (zh) * 2007-02-09 2009-12-09 Irm责任有限公司 作为通道活化蛋白酶抑制剂的化合物和组合物
AU2008219704A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2463284A1 (en) 2007-02-27 2012-06-13 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP2010522172A (ja) * 2007-03-23 2010-07-01 シェーリング コーポレイション Ｈｃｖｎｓ３プロテアーゼのｐ１−非エピメリ化ケトアミド阻害剤
EP2160392A2 (en) * 2007-05-03 2010-03-10 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
NZ580917A (en) 2007-05-04 2012-06-29 Vertex Pharma Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection
BRPI0811447A2 (pt) * 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
TW200924751A (en) * 2007-08-29 2009-06-16 Schering Corp 2,3-substituted indole derivatives and methods of use thereof
CN101821252A (zh) * 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
KR20100065167A (ko) 2007-08-29 2010-06-15 쉐링 코포레이션 바이러스 감염 치료용 2,3-치환된 아자인돌 유도체
AU2008297015B2 (en) 2007-08-30 2013-08-22 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
NZ583825A (en) * 2007-09-14 2012-06-29 Schering Corp Method of treating hepatitis C patients comprising an HCV protease inhibitor, an antiviral compound and an interferon
CN101868452B (zh) 2007-10-10 2014-08-06 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
MX2010005355A (es) * 2007-11-16 2010-06-02 Schering Corp Derivados de indol sustituidos con 3-aminosulfonilo y metodos de uso de los mismos.
US8765757B2 (en) * 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
MX2010005809A (es) * 2007-11-28 2010-06-09 Schering Corp Proceso de dehidrohalogenacion para la preparacion de intermediarios utiles en el suministro de compuestos 6,6-dimetil-3-azabiciclo-[3,1,0]-hexano.
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR071270A1 (es) * 2007-12-21 2010-06-09 Schering Corp Proceso para la sintesis de 3- amino-3 ciclobutilmetil -2- hidroxipropionamida y uso del mismo
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
AR070413A1 (es) 2008-02-04 2010-04-07 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de proteasa de serina
WO2009142842A2 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102046648A (zh) 2008-05-29 2011-05-04 百时美施贵宝公司 丙型肝炎病毒抑制剂
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
CA2724523A1 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
MX2010013630A (es) * 2008-06-13 2010-12-21 Schering Corp Derivados triciclicos de indol y metodos de uso de los mismos.
ES2438576T3 (es) 2008-06-24 2014-01-17 Codexis, Inc. Procesos biocatalíticos para la preparación de compuestos de prolina bicíclica fusionada considerablemente pura estereoméricamente
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282574B2 (en) 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009303483A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010076329A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
AR077139A1 (es) 2009-06-23 2011-08-03 Gilead Sciences Inc Composiciones farmaceuticas utiles para tratar el vch
TW201109335A (en) 2009-08-04 2011-03-16 Takeda Pharmaceutical Heterocyclic compounds
EP2461811B1 (en) 2009-08-05 2016-04-20 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011031904A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
JP2013505952A (ja) * 2009-09-28 2013-02-21 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新しい大環状阻害剤
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2516430B1 (en) 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2539334A1 (en) * 2010-02-25 2013-01-02 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg Process for the preparation of -acyloxy -formamido amides
BR112012022125A2 (pt) 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
JP2013541499A (ja) 2010-07-26 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012109398A1 (en) 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
DE202012012956U1 (de) 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US20130123325A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
WO2013178682A2 (en) * 2012-05-30 2013-12-05 Chemo Ibérica, S.A. Multicomponent process for the preparation of bicyclic compounds
CN103508918B (zh) * 2012-06-18 2015-09-09 上海医药工业研究院 带有环丁基的α-羟基β-氨基酯类化合物及其制备方法
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
WO2014061034A1 (en) * 2012-10-18 2014-04-24 Msn Laboratories Limited Process for preparation of boceprevir and intermediates thereof
HRP20161694T1 (hr) 2012-10-19 2017-03-10 Bristol-Myers Squibb Company 9-metil supstituirani heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4) diazaciklopentadecinil karbamat derivati kao ne-strukturalni 3 (ns3) proteazni inhibitori za liječenje infekcija virusom hepatitisa c
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014083575A2 (en) 2012-11-29 2014-06-05 Mylan Laboratories Ltd Improved process for the preparation of boceprevir intermediate
CN103936818B (zh) * 2013-01-18 2017-09-29 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅰ及其制备方法和应用
CN103936652B (zh) * 2013-01-18 2016-07-06 上海医药工业研究院 抗丙肝药物Boceprevir的中间体IV及其制备方法和应用
CN103936627B (zh) * 2013-01-18 2016-08-31 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅶ及其制备方法和应用
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20150131276A (ko) 2013-03-14 2015-11-24 오닉스 세라퓨틱스, 인크. 디펩타이드 및 트리펩타이드 에폭시 케톤 프로테이스 억제제
AR095426A1 (es) * 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
CN103387510B (zh) * 2013-08-08 2015-09-09 苏州永健生物医药有限公司 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US10035760B2 (en) * 2013-10-24 2018-07-31 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CN106810485A (zh) * 2015-11-27 2017-06-09 上海现代制药股份有限公司 一种手性联苯吡咯烷酮的制备方法及其中间体
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
UA124672C2 (uk) 2016-06-21 2021-10-27 Оріон Офтальмолоджі Ллс Гетероциклічні похідні пролінаміду
EA201990070A1 (ru) * 2016-06-21 2019-06-28 ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи Производные алифатического пролинамида
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides
WO2018134127A1 (en) 2017-01-23 2018-07-26 Basf Se Fungicidal pyridine compounds
EP3606914A1 (en) 2017-04-06 2020-02-12 Basf Se Pyridine compounds
EP3618847B1 (en) 2017-05-05 2021-04-07 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
EP3927703B1 (en) 2019-02-19 2023-04-05 Univerza V Ljubljani Antibacterials based on monocyclic fragments coupled to aminopiperidine naphthyridine scaffold
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
IL300027A (en) * 2020-07-20 2023-03-01 Enanta Pharm Inc Peptides that function as antiviral agents
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CA3202764A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
EP4438122A3 (en) * 2021-04-16 2024-12-18 Fujian Akeylink Biotechnology Co., Ltd. Ring-modified proline short peptide compound and use thereof
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
WO2023086352A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2023086400A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
WO2023107419A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
US12145941B2 (en) 2021-12-08 2024-11-19 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
CN114133350B (zh) * 2021-12-16 2023-05-23 浙江乐普药业股份有限公司 一种抗新冠药物Paxlovid中间体的制备方法
WO2023149981A1 (en) * 2022-02-07 2023-08-10 Purdue Research Foundation Compounds for the treatment of sars
WO2023196307A1 (en) 2022-04-05 2023-10-12 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
CN114736151B (zh) * 2022-04-13 2023-04-21 湖南复瑞生物医药技术有限责任公司 一种帕罗韦德关键中间体制备方法及化合物的结构式
CN115160205B (zh) * 2022-07-08 2024-06-07 上海皓鸿生物医药科技有限公司 一种制备(s)-1-(叔丁氧羰基)-2,5-二氢-1h-吡咯-2-羧酸及盐的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007734A2 (en) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
WO2000052032A1 (en) * 1999-03-03 2000-09-08 Dainippon Pharmaceutical Co., Ltd. Heterocyclic compounds, intermediates thereof and elastase inhibitors
WO2001040262A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
WO2001074768A2 (en) * 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177134B (en) * 1977-07-18 1981-07-28 Richter Gedeon Vegyeszet Process for preparing angiotensin ii analogues containing alpha-hydroxy-acid in position 1 with angiotensin ii antagonist activity
DE2936099A1 (de) * 1979-09-06 1981-04-02 Victor Dipl.- Chem. 8000 München Brantl Pharmakologisch aktive peptide
JPS5781447A (en) * 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
DE3481913D1 (de) * 1983-04-27 1990-05-17 Ici America Inc Prolin-derivate.
AU600226B2 (en) 1985-02-04 1990-08-09 Merrell Pharmaceuticals Inc. Novel peptidase inhibitors
US5496927A (en) * 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
CN1049686C (zh) 1987-11-18 2000-02-23 希龙股份有限公司 非ａ和非ｂ肝炎病毒的诊断及疫苗
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
DE69024378T2 (de) 1989-02-01 1996-09-12 Asahi Glass Co. Ltd., Tokio/Tokyo Azeotrope oder azeotropähnliche Zusammensetzung auf der Basis von Chlorfluorkohlenwasserstoffen
US5359138A (en) * 1989-04-15 1994-10-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
WO1990012805A1 (fr) * 1989-04-15 1990-11-01 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Postostatine et son compose connexe, ou leurs sels
DE69133617D1 (de) 1990-04-04 2009-07-23 Novartis Vaccines & Diagnostic Protease von Hepatitis C Virus
JP2804817B2 (ja) 1990-04-13 1998-09-30 財団法人微生物化学研究会 ３―アミノ―２―オキソ脂肪酸誘導体の製造法
JPH04149166A (ja) 1990-10-12 1992-05-22 Nippon Kayaku Co Ltd 新規ケト酸アミド誘導体
JPH06504061A (ja) 1990-12-28 1994-05-12 コーテックス　ファーマシューティカルズ　インコーポレイテッド 神経変性の治療および予防におけるカルパイン阻害剤の使用
FR2686086A1 (fr) * 1992-01-15 1993-07-16 Adir Nouveaux derives de peptides et de pseudopeptides therapeutiquement actifs dans la cascade de coagulation sanguine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CA2129733C (en) * 1992-01-31 2006-10-31 James M. Casey Mammalian expression systems for hcv proteins
JPH09500087A (ja) 1992-06-24 1997-01-07 コーテックス ファーマシューティカルズ インコーポレイテッド カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
US5414018A (en) * 1993-09-24 1995-05-09 G. D. Searle & Co. Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension
US5843450A (en) * 1994-02-14 1998-12-01 Abbott Laboratories Hepatitis GB Virus synthetic peptides and uses thereof
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US6285380B1 (en) * 1994-08-02 2001-09-04 New York University Method and system for scripting interactive animated actors
RU2104284C1 (ru) * 1994-10-20 1998-02-10 Научно-исследовательский институт вирусологии им.Д.И.Ивановского РАМН Синтетические олигопептиды, специфически взаимодействующие с антителами к вирусу гепатита с, способы диагностики hcv-инфекции (варианты)
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US5919765A (en) 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
US5763576A (en) * 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
IL120310A (en) 1996-03-01 2002-02-10 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
WO1998007734A1 (en) 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs
IT1285158B1 (it) 1996-09-17 1998-06-03 Angeletti P Ist Richerche Bio Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il
BR9712115A (pt) 1996-09-24 1999-08-31 Procter & Gamble Detergentes líquidos contendo enzima proteolítica, aldeído peptídeo e uma fonte de ácido bórico.
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
IN183120B (enExample) * 1996-10-18 1999-09-11 Vertex Pharma
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
JP2001508418A (ja) 1996-12-27 2001-06-26 ベーリンガー インゲルハイム（カナダ）リミテッド ヒトサイトメガロウイルスプロテアーゼのペプチドミメティックインヒビター
WO1998037180A2 (en) 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
IL134232A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptides
GB9809664D0 (en) 1998-05-06 1998-07-01 Hoffmann La Roche a-Ketoamide derivatives
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6576613B1 (en) * 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
MY139078A (en) * 2000-07-21 2009-08-28 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007734A2 (en) * 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
WO2000052032A1 (en) * 1999-03-03 2000-09-08 Dainippon Pharmaceutical Co., Ltd. Heterocyclic compounds, intermediates thereof and elastase inhibitors
WO2001040262A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
WO2001074768A2 (en) * 2000-04-03 2001-10-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101020355B1 (ko) * 2002-01-18 2011-03-08 덴드레온 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드

Also Published As

Publication number Publication date
RU2355700C9 (ru) 2010-03-20
LU91910I2 (fr) 2012-02-02
TWI324611B (en) 2010-05-11
NO2013003I1 (no) 2013-03-04
CZ2003151A3 (cs) 2003-05-14
ES2341534T3 (es) 2010-06-22
US20040254117A9 (en) 2004-12-16
NO332329B1 (no) 2012-09-03
CA2410662C (en) 2012-09-18
DE122012000004I1 (de) 2012-04-26
CY1112267T1 (el) 2015-12-09
WO2002008244A3 (en) 2003-06-19
CN102206247B (zh) 2013-03-27
US7012066B2 (en) 2006-03-14
HK1058047A1 (en) 2004-04-30
MXPA03000627A (es) 2004-07-30
CN102372764A (zh) 2012-03-14
SK752003A3 (en) 2003-08-05
IL153670A0 (en) 2003-07-06
PL366063A1 (en) 2005-01-24
HU229997B1 (en) 2015-04-28
JP5775505B2 (ja) 2015-09-09
JP2009051860A (ja) 2009-03-12
KR20030025277A (ko) 2003-03-28
WO2002008244A2 (en) 2002-01-31
NO20030272D0 (no) 2003-01-20
AU7698801A (en) 2002-02-05
US20110117057A1 (en) 2011-05-19
MY139078A (en) 2009-08-28
NO20030272L (no) 2003-03-21
SI1385870T1 (sl) 2010-08-31
HUP0401730A3 (en) 2012-09-28
PT1385870E (pt) 2010-06-07
DE60141608D1 (de) 2010-04-29
KR100939155B1 (ko) 2010-01-28
CY2011020I1 (el) 2016-12-14
NO2013003I2 (no) 2017-01-16
DK1385870T3 (da) 2010-07-05
RU2008126266A (ru) 2010-01-10
ATE461207T1 (de) 2010-04-15
CN1498224A (zh) 2004-05-19
AR069373A2 (es) 2010-01-20
JP2004504404A (ja) 2004-02-12
MY143322A (en) 2011-04-15
JP4298289B2 (ja) 2009-07-15
EP1385870B1 (en) 2010-03-17
ECSP034438A (es) 2003-03-10
USRE43298E1 (en) 2012-04-03
SK288064B6 (sk) 2013-04-03
AU2001276988B2 (en) 2007-01-25
IL153670A (en) 2012-06-28
US20030216325A1 (en) 2003-11-20
RU2355700C2 (ru) 2009-05-20
US20060205672A1 (en) 2006-09-14
CA2410662A1 (en) 2002-01-31
PL206255B1 (pl) 2010-07-30
JP2013032389A (ja) 2013-02-14
CY2011020I2 (el) 2016-12-14
AR033985A1 (es) 2004-01-21
NZ523782A (en) 2005-10-28
HUP0401730A2 (hu) 2004-12-28
KR20090030330A (ko) 2009-03-24
CN102206247A (zh) 2011-10-05
BR0112540A (pt) 2003-06-24
EP1385870A2 (en) 2004-02-04
CZ303213B6 (cs) 2012-05-23
ZA200210312B (en) 2004-03-29

Similar Documents

Publication Publication Date Title
KR100904788B1 (ko) Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
KR101020355B1 (ko) Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
EP1301486B1 (en) Imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
JP4748912B2 (ja) アルキルおよびアリールアラニンｐ２部分を含むｃ型肝炎ウイルスに対する大員環ｎｓ３−セリンプロテアーゼ阻害剤
US20050249702A1 (en) (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
US20020147139A1 (en) Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2001276988A1 (en) Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR20030036152A (ko) Ｎ-사이클릭 ｐ2 잔기를 포함하는 ｃ형 간염 바이러스의매크로사이클릭 ｎｓ3-세린 프로테아제 억제제
JP2004513881A (ja) Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
KR20060124729A (ko) Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의 억제제로서의신규한 화합물
KR20060118532A (ko) Ｃ형 간염 바이러스 ｎｓ３／ｎｓ４ａ 세린 프로테아제의억제제
HK1144439A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
HK1058047B (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20130531

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20140529

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 20, Claim Number : 1 4, 7 14, 17, 25 28, 38, 39, 53, Period Limitation Text : 940, Comment Text : 151

St.27 status event code: A-4-4-G10-G18-tex-PA0101

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PE0702 Decision to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 20, Claim Number : 1 4, 7 14, 17, 25 28, 38, 39, 53, Period Limitation Text : 940, Comment Text : 151

St.27 status event code: A-4-4-G10-G20-tex-PE0702

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 8

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 9

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20180620

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180620

St.27 status event code: N-4-6-H10-H13-oth-PC1903